Wong Y F, Chung T K, Cheung T H, Lam S K, Tam O S, Lu H J, Xu F D, Chang A M
Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong.
J Obstet Gynaecol Res. 1996 Apr;22(2):171-5. doi: 10.1111/j.1447-0756.1996.tb00961.x.
To determine the amplification of proto-oncogene HER-2/neu in invasive cervical cancer and its relationship with the stage of disease, grade of tumor and prognosis of patients.
In this retrospective study 70 women with invasive cervical squamous cell carcinoma were included. DNA was extracted from the paraffin-embedded tumor tissue. The amplification of HER-2/neu was studied using a differential polymerase reaction (PCR) technique. Assessment of significance was performed using Peason's Chi-square test and Fisher's exact test.
Eleven of the 70 cases (16%) showed an amplification of HER-2/neu but there was no relation between amplification and tumor histologic grading (p = 0.408) or clinical staging (p = 0.180). Follow-up information in 67 patients was available. The incidence of amplification in the patients who were alive with disease was not statistically different from that in the patients who were alive with no evidence of disease (p = 0.315). The incidence of amplification in the patients who died of disease was higher than that in the patients who were still alive, but statistical significance did not reached (p = 0.062).
The results suggest that HER-2/neu amplification does exist in a subgroup of invasive cervical cancer and may play a role in cervical carcinogenesis. The role as independent prognostic factor has to be evaluated by further prospective studies.
确定原癌基因HER-2/neu在浸润性宫颈癌中的扩增情况及其与疾病分期、肿瘤分级和患者预后的关系。
本回顾性研究纳入了70例浸润性宫颈鳞状细胞癌女性患者。从石蜡包埋的肿瘤组织中提取DNA。采用差异聚合酶反应（PCR）技术研究HER-2/neu的扩增情况。使用Pearson卡方检验和Fisher精确检验进行显著性评估。
70例病例中有11例（16%）显示HER-2/neu扩增，但扩增与肿瘤组织学分级（p = 0.408）或临床分期（p = 0.180）之间无相关性。有67例患者的随访信息可用。疾病存活患者的扩增发生率与无疾病证据存活患者的扩增发生率无统计学差异（p = 0.315）。死于疾病患者的扩增发生率高于仍存活患者，但未达到统计学显著性（p = 0.062）。
结果表明HER-2/neu扩增在浸润性宫颈癌的一个亚组中确实存在，可能在宫颈癌发生中起作用。其作为独立预后因素的作用有待进一步前瞻性研究评估。
